Baseline patient characteristics
| Characteristic . | BV/Len (n = 37) . | |
|---|---|---|
| . | n . | % . |
| Median age, y (range) | 65 (51-79) | |
| Baseline ECOG performance status | ||
| 0-1 | 28 | 76 |
| 2 | 8 | 21 |
| Unknown | 1 | 3 |
| IPI score at study entry | ||
| 0 | 3 | 8 |
| 1 | 3 | 8 |
| 2 | 17 | 46 |
| 3 | 8 | 22 |
| 4 | 4 | 11 |
| 5 | 2 | 5 |
| Transformed disease | 9 | 24 |
| Elevated LDH | 20 | 54 |
| Cell of origin by IHC | ||
| GCB | 20 | 54 |
| Non-GCB | 17 | 46 |
| Time from initial diagnosis, months | ||
| Median (range) | 14 (4-138) | |
| Stage at study screening | ||
| Stages I and II | 9 | 24 |
| Stages III and IV | 28 | 76 |
| Median prior therapies (range) | 3 (1-6) | |
| Primary refractory | 17 | 46 |
| Refractory to most recent treatment | 20 | 54 |
| Patients with prior rituximab exposure | 37 | 100 |
| Bulky disease (≥7.5 cm) | 13 | 35 |
| Prior stem cell transplant | 10 | 27 |
| Reason why ineligible for ASCT | ||
| Age | 9 | 33 |
| Comorbidities | 1 | 3 |
| Inadequate response to salvage | 17 | 64 |
| Characteristic . | BV/Len (n = 37) . | |
|---|---|---|
| . | n . | % . |
| Median age, y (range) | 65 (51-79) | |
| Baseline ECOG performance status | ||
| 0-1 | 28 | 76 |
| 2 | 8 | 21 |
| Unknown | 1 | 3 |
| IPI score at study entry | ||
| 0 | 3 | 8 |
| 1 | 3 | 8 |
| 2 | 17 | 46 |
| 3 | 8 | 22 |
| 4 | 4 | 11 |
| 5 | 2 | 5 |
| Transformed disease | 9 | 24 |
| Elevated LDH | 20 | 54 |
| Cell of origin by IHC | ||
| GCB | 20 | 54 |
| Non-GCB | 17 | 46 |
| Time from initial diagnosis, months | ||
| Median (range) | 14 (4-138) | |
| Stage at study screening | ||
| Stages I and II | 9 | 24 |
| Stages III and IV | 28 | 76 |
| Median prior therapies (range) | 3 (1-6) | |
| Primary refractory | 17 | 46 |
| Refractory to most recent treatment | 20 | 54 |
| Patients with prior rituximab exposure | 37 | 100 |
| Bulky disease (≥7.5 cm) | 13 | 35 |
| Prior stem cell transplant | 10 | 27 |
| Reason why ineligible for ASCT | ||
| Age | 9 | 33 |
| Comorbidities | 1 | 3 |
| Inadequate response to salvage | 17 | 64 |
ECOG, Eastern Cooperative Oncology Group; IHC, immunohistochemistry; LDH, lactate dehydrogenase.